[Liver]
function test
abnormalities in ICU patients, 549
role of, in host defense mechanisms, 341
severity of, disease
Child–Pugh classification of, 341–342
LRINEC score.SeeLaboratory Risk Indicator
for Necrotizing Fasciitis (LRINEC)
score
LTBI.SeeLatent tuberculosis infection (LTBI)
Lumbar puncture (LP), 150
Lumbosacral plexopathy, physical findings
diagnostic features, 63
noninfectious mimics, 63
PE findings, 63
Lungs
cavity, 94
transplantation, 388–389
recipients, mediastinitis in, 398
Lupus (SLE) pneumonitis, 93
Lyme disease, 29–30, 71, 157–158
Lymphadenopathy, physical findings
diagnostic features, 55
noninfectious mimics, 55
Lymphadenopathy
axillary.SeeAxillary lymphadenopathy, physical
findings
bicipital.SeeBicipital lymphadenopathy,
physical findings
cervical.SeeCervical lymphadenopathy,
physical findings
generalized.SeeGeneralized lymphadenopathy,
physical findings
inguinal.SeeInguinal lymphadenopathy,
physical findings
occipital.SeeOccipital lymphadenopathy,
physical findings
preauricular.SeePreauricular
lymphadenopathy, physical findings
submandibular.SeeSubmandibular
lymphadenopathy, physical findings
supra-clavicular.SeeSupra-clavicular
lymphadenopathy, physical findings
Lymphedema, 298, 299
Lymphoma, CNS, 89
Lyssa virus, 480
Macrolides, 537
Macrophage activation syndrome (MAS), 384
Macular star, 70
Maculopapular rashes, 29–33, 332
drug exanthems, 30
drug reaction, 30
erythema multiforme, 30–31
Lyme disease, 29–30
secondary syphilis, 32
Stevens–Johnson syndrome, 31
TEN, 31–32
WNV, 32–33
Mafenide acetate, 361, 362
Magnetic resonance imaging (MRI), 90
contrast-enhanced sagittal, of brain, 91
Malaria, 324–325
artemesinins, 325–326
quinidine gluconate, 325
severe, treatment of, 333–334
Malassezia furfur
skin and soft tissue infections and, 296
MALT lymphoma.SeeMucosa-associated
lymphoid tissue (MALT) lymphoma
Manget, John Jacobus, 420
Marantic endocarditis, 211
Marburg hemorrhagic fever, 476
Marburg virus, 332
MAS.SeeMacrophage activation syndrome (MAS)
Mast cells, 525, 544
MDR.SeeMultidrug resistant (MDR)
MDRA. baumannii
antimicrobial therapy, 518
clinical significance of, 518
empiric therapy of, 517–519
epidemiology, 517
infections of, 517
MDRK. pneumoniae, 516
antibiotic therapy of, 516–517
antimicrobial therapy, 518
clinical significance of, 518
infection of, 516
MDRP. aeruginosa
antibiotic therapy of, 515–516
antimicrobial therapy, 518
clinical significance of, 518
epidemiology, 514
MDR pathogens.SeeMultidrug resistant (MDR)
pathogens
MDR TB.SeeMultidrug-resistant (MDR) TB
Measles, 332
Mediastinitis, in heart and lung transplant
recipients, 398
Medical intensive care unit (MICU), 110
Melioidosis, 328
Meningitis, 14, 113, 153
aseptic, 153
bacterial, 153
brain and, 135
in burn patients, 372
clinical and laboratory features of, 138
clinical and radiologic diagnosis of, 90
clinical approach in, 135
collagen vascular diseases, 137–138
complications of, 142
CSF gram stain clues in, 145
CSF in.SeeCerebrospinal fluid (CSF)
drug-induced, 136–137
empiric therapy of, 148–150
host–pathogen association in, 141
lumbar puncture, 150
mimics of, 90, 135, 139–140
noninfectious, 136–138
neuroimaging tests, 148
pathogens in, prediction of, 138570 Index